Literature DB >> 20558367

Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks.

Vernon J Lee1, Jonathan Yap, Alex R Cook, Mark I Chen, Joshua K Tay, Boon Huan Tan, Jin Phang Loh, Seok Wei Chew, Wee Hong Koh, Raymond Lin, Lin Cui, Charlie W H Lee, Wing-Kin Sung, Christopher W Wong, Martin L Hibberd, Wee Lee Kang, Benjamin Seet, Paul A Tambyah.   

Abstract

BACKGROUND: From June 22 through June 25, 2009, four outbreaks of infection with the pandemic influenza A (H1N1) virus occurred in Singapore military camps. We report the efficacy of ring chemoprophylaxis (geographically targeted containment by means of prophylaxis) with oseltamivir to control outbreaks of 2009 H1N1 influenza in semiclosed environments.
METHODS: All personnel with suspected infection were tested and clinically isolated if infection was confirmed. In addition, we administered postexposure ring chemoprophylaxis with oseltamivir and segregated the affected military units to contain the spread of the virus. All personnel were screened three times weekly both for virologic infection, by means of nasopharyngeal swabs and reverse-transcriptase-polymerase-chain-reaction assay with sequencing, and for clinical symptoms, by means of questionnaires.
RESULTS: A total of 1175 personnel were at risk across the four sites, with 1100 receiving oseltamivir prophylaxis. A total of 75 personnel (6.4%) were infected before the intervention, and 7 (0.6%) after the intervention. There was a significant reduction in the overall reproductive number (the number of new cases attributable to the index case), from 1.91 (95% credible interval, 1.50 to 2.36) before the intervention to 0.11 (95% credible interval, 0.05 to 0.20) after the intervention. Three of the four outbreaks showed a significant reduction in the rate of infection after the intervention. Molecular analysis revealed that all four outbreaks were derived from the New York lineage of the 2009 H1N1 virus and that cases within each outbreak were due to transmission rather than unrelated episodes of infection. Of the 816 personnel treated with oseltamivir who were surveyed, 63 (7.7%) reported mild, nonrespiratory side effects of the drug, with no severe adverse events.
CONCLUSIONS: Oseltamivir ring chemoprophylaxis, together with prompt identification and isolation of infected personnel, was effective in reducing the impact of outbreaks of 2009 H1N1 influenza in semiclosed settings. Copyright 2010 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558367     DOI: 10.1056/NEJMoa0908482

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  41 in total

1.  Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Authors:  Elena A Govorkova; Bindumadhav M Marathe; Ashley Prevost; Jerold E Rehg; Robert G Webster
Journal:  Antiviral Res       Date:  2011-05-27       Impact factor: 5.970

2.  Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.

Authors:  Luis R Carrasco; Vernon J Lee; Mark I Chen; David B Matchar; James P Thompson; Alex R Cook
Journal:  J R Soc Interface       Date:  2011-02-04       Impact factor: 4.118

3.  Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.

Authors:  Marc Lipsitch; Lyn Finelli; Richard T Heffernan; Gabriel M Leung; Stephen C Redd
Journal:  Biosecur Bioterror       Date:  2011-06

4.  We should not be complacent about our population-based public health response to the first influenza pandemic of the 21st century.

Authors:  Heath A Kelly; Patricia C Priest; Geoffry N Mercer; Gary K Dowse
Journal:  BMC Public Health       Date:  2011-02-03       Impact factor: 3.295

5.  Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.

Authors:  Deshi Shi; Dongfang Yang; Eric P Prinssen; Brian E Davies; Bingfang Yan
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

6.  IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus.

Authors:  Chenggang Li; Penghui Yang; Yang Sun; Taisheng Li; Chen Wang; Zhong Wang; Zhen Zou; Yiwu Yan; Wei Wang; Chen Wang; Zhongwei Chen; Li Xing; Chong Tang; Xiangwu Ju; Feng Guo; Jiejie Deng; Yan Zhao; Peng Yang; Jun Tang; Huanling Wang; Zhongpeng Zhao; Zhinan Yin; Bin Cao; Xiliang Wang; Chengyu Jiang
Journal:  Cell Res       Date:  2011-10-25       Impact factor: 25.617

Review 7.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

8.  The role of symptomatic presentation in influenza A transmission risk.

Authors:  R Wardell; K Prem; B J Cowling; A R Cook
Journal:  Epidemiol Infect       Date:  2016-12-05       Impact factor: 2.451

Review 9.  Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Authors:  Deeva Berera; Maria Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

10.  Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants.

Authors:  Weng Ieong Tou; Kun-Lung Chang; Tung-Ti Chang; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  J Mol Model       Date:  2015-12-08       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.